Kymera Therapeutics (KYMR) EBT Margin (2019 - 2025)
Historic EBT Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 3350.9%.
- Kymera Therapeutics' EBT Margin fell 14213700.0% to 3350.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 139746.22%, marking a year-over-year increase of 1399751200.0%. This contributed to the annual value of 8447.87% for FY2024, which is 82370000.0% down from last year.
- Per Kymera Therapeutics' latest filing, its EBT Margin stood at 3350.9% for Q3 2025, which was down 14213700.0% from 737.76% recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' EBT Margin ranged from a high of 220.94% in Q4 2024 and a low of 3350.9% during Q3 2025
- In the last 5 years, Kymera Therapeutics' EBT Margin had a median value of 337.1% in 2025 and averaged 574.39%.
- Per our database at Business Quant, Kymera Therapeutics' EBT Margin surged by 2987000bps in 2021 and then tumbled by -14213700bps in 2025.
- Quarter analysis of 5 years shows Kymera Therapeutics' EBT Margin stood at 222.88% in 2021, then decreased by -8bps to 239.72% in 2022, then soared by 83bps to 40.44% in 2023, then surged by 646bps to 220.94% in 2024, then tumbled by -1617bps to 3350.9% in 2025.
- Its last three reported values are 3350.9% in Q3 2025, 737.76% for Q2 2025, and 337.1% during Q1 2025.